Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Soligenix has filed a Form S-8 to register securities under its 2025 Equity Incentive Plan. The company, headquartered in Princeton, New Jersey, is classified as both a non-accelerated filer and a smaller reporting company.
Key filing incorporations include:
- Annual Report on Form 10-K for FY2024 (filed March 21, 2025)
- Q1 2025 Form 10-Q (filed May 9, 2025)
- Recent Form 8-K filings from February, March, and June 2025
The registration includes comprehensive indemnification provisions for directors and officers under Delaware law, including protection against personal liability for fiduciary duty breaches, except in cases of:
- Breach of duty of loyalty
- Acts not in good faith or involving intentional misconduct
- Unlawful dividend payments or stock repurchases
- Improper personal benefit transactions